Esophageal carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Presently, the single nucleotide polymorphisms (SNPs) of EGFR/PLCE1 genes and their associations with EC survival remain unclear.
|
31209807 |
2019 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR), the efficacy of nimotuzumab added to nCRT for esophageal cancer is uncertain.
|
31258850 |
2019 |
Esophageal carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Results indicated that PT shows more effective antitumor activity as compared with Pan both on EGFR-overexpressed KYSE-450 and KYSE-150 esophageal cancer cells, especially on KYSE-450 cells.
|
30596104 |
2018 |
Esophageal carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR mutation in the peripheral blood of patients with esophageal carcinoma was unrelated to the gender, age, and the location of the tumor (P < 0.05).
|
29516969 |
2018 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results indicated that miR-133a could inhibit the MEK/ERK pathway to promote cell apoptosis and enhance radio-sensitivity by targeting EGFR in EC..
|
27933650 |
2017 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Results of this study suggest that anti-EGFR therapies should be investigated in prospective clinical trials in different settings in EGFR FISH-positive and, in particular, EGFR-amplified esophageal cancer.
|
28537764 |
2017 |
Esophageal carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In this study, we first evaluated EGFR gene and protein expression in 70 Chinese EC patient tumor samples collected during surgery.
|
28881608 |
2017 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
|
28498434 |
2017 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These phase 3 trial results point to little benefit to current EGFR-targeted agents in an unselected patient population, and highlight the need for predictive biomarkers in the treatment of esophageal cancer.
|
28687830 |
2017 |
Esophageal carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We also observed a significant increase in ERCC1 expression, and decrease in p53 and EGFR expression, in EC-9706 cells treated with SNX-2112 (P < 0.05), indicating the regulation of EC by SNX-2112.
|
27420968 |
2016 |
Esophageal carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Real-time quantitative polymerase chain reaction technology (RT-PCR) was used to detect the expression of VEGF, HER-2, and EGFR mRNA in esophageal squamous cancer tissue of 60 cases and 30 cases of VEGF, HER-2, and EGFR mRNA in esophageal cancer adjacent tissues, and analyze its relationship with clinicopathological features.
|
26099724 |
2015 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expression and prognostic influence of NF-κB and EGFR in esophageal cancer.
|
26681028 |
2015 |
Esophageal carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Both YAP1 and EGFR are overexpressed in resistant esophageal cancer tissues compared with sensitive esophageal cancer tissues.
|
25739674 |
2015 |
Esophageal carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
|
25070024 |
2014 |
Esophageal carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.
|
23377570 |
2014 |
Esophageal carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
More than 50% EGFR-positive EsC and MPM cells were resistant to EGFR-TKI, and susceptibility to EGFR-TKI growth-inhibitory effect correlated positively with expression of E-cadherin (epithelial gene marker) and negatively with mesenchymal gene markers.
|
23749888 |
2013 |
Esophageal carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of epidermal growth factor receptor in esophageal cancer is associated with poor prognosis.
|
22555809 |
2012 |
Esophageal carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In this report, the effect of PYM on EGFR expression in human esophageal cancer cells and the therapeutic efficacy of the combination of PYM and cetuximab on esophageal cancer xenograft were investigated.
|
22311160 |
2012 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We evaluated the antitumor effects of lapatinib, a dual tyrosine kinase inhibitor which simultaneously inhibits EGFR and HER2, 5-fluorouracil (5-Fu) alone and in combination on esophageal cancer cells.
|
22293713 |
2012 |
Esophageal carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We report the outcome in a series of esophageal cancer patients treated at our center and the results of a retrospective analysis of epidermal growth factor receptor (EGFR) expression and EGFR/HER2 gene copy numbers taken as possible prognostic and predictive factors.
|
23052161 |
2012 |
Esophageal carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations of EGFR and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) have been identified in esophageal carcinoma, but corresponding Chinese data are limited.
|
21615826 |
2011 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
|
21207425 |
2011 |
Esophageal carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The EGFR CA repeat genetic polymorphism may act as a valuable molecular predictor of clinical outcome of esophageal cancer after CCRT and esophagectomy, especially in those with good response to CCRT.
|
21298351 |
2011 |
Esophageal carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Irradiation combined with EGFR blocked by cetuximab may reverse the resistance to radiation in radioresistant esophageal carcinoma cell.
|
19744737 |
2009 |